当前位置： SCI文献检索 > ORVOSI HETILAP期刊下所有文献 > [Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary].

[Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary].

Abstract：

UNLABELLED:Rheumatoid arthritis (RA) is a chronic, progressive polyarthritis leading to substantial disability. Standardised data on consequences of disease progression are needed for clinical assessments and also for cost-effectiveness models. AIM:To analyse the impact of disease progression on health status, disease specific quality of life and costs in Hungary. METHODS:A cross-sectional survey was performed between April and August, 2004, involving consecutive RA patients of 6 hospital based rheumatology outpatient centres. Self-completed questionnaires were used to assess functional (HAQ) and health status (EQ-5D), quality of life (RAQoL). Disease activity (DAS) and costs were also surveyed, statistical analysis was performed. RESULTS:255 patients were involved [mean age 55.5 +/- 12.3 years; disease duration 9.0 +/- 9.3 years; HAQ 1.38 +/- 0.76; EQ-5D 0.46 +/- 0.33; RAQoL 16.2 +/- 8.1; DAS 5.09 +/- 1.42; costs 1,043,163 (+/- 844,750) HUF/patient/year, conversion 1 Euro = 250 HUF]. Correlation was significant between the parameters ( p < 0.01): EQ-5D index = 1.014 - 0.25 x HAQ-0.041 x DAS; HAQ = 0.314 + 0.065 x RAQoL. Analysis by disease severity levels (HAQ groups 0.5 difference) revealed that health status worsens (mean EQ-5D: 0.784; 0.576; 0.504; 0.367; 0.211; 0.022) and costs increase (mean 628,280; 888,187; 953,759; 1,291,218; 1,346,112; 1,371,674 HUF/patient/year) with disease progression. Minimally important worsening of functional ability (0.25 HAQ increase) corresponds to -0.0705 EQ-5D and +1.884 RAQoL change. Lower health status difference (EQ-5D -0.05725) was calculated in patients with lower disease activity (DAS < 5.1). CONCLUSIONS:Correlation between disease progression, health status, quality of life and costs does not differ significantly from international results. The amount of costs is much lower in all disease severity levels than in developed European countries. Our study serves baseline data for health economic analysis in RA in Hungary.

journal_name

Orv Hetil

journal_title

Orvosi hetilap

authors

Péntek M,Szekanecz Z,Czirják L,Poór G,Rojkovich B,Polgár A,Genti G,Kiss CG,Sándor Z,Májer I,Brodszky V,Gulácsi L

doi

10.1556/OH.2008.28294

subject

Has Abstract

pub_date

2008-04-20 00:00:00

pages

733-41

issue

eissn

0030-6002

issn

1788-6120

pii

J358229040768452

journal_volume

149

pub_type

杂志文章

在线工具

[Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary].